Obio Technology (Shanghai) Corp., Ltd. (SHA:688238)

China · Delayed Price · Currency is CNY

7.09

-0.06 (-0.84%)

At close: Feb 13, 2026

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Cell and Gene Therapy Contract Development and Manufacturing Organization	134.94M
Cell and Gene Therapy Contract Development and Manufacturing Organization Growth	26.12%
Cell and Gene Therapy Contract Research Organization	85.82M
Cell and Gene Therapy Contract Research Organization Growth	8.02%
Biological Agents, Reagents and Others	23.94M
Biological Agents, Reagents and Others Growth	35.97%
Regenerative Medicine Services	316.96K
Other	3.13M
Other Growth	312.81%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	243.40M
China Growth	19.03%
Overseas	1.62M
Overseas Growth	414.41%